Cwestiynau Llafar y Cynulliad a gyflwynwyd ar 14 Ionawr 2015 i'w hateb ar 21 Ionawr 2015
R - Yn dynodi bod yr Aelod wedi datgan buddiant.
W - Yn dynodi bod y cwestiwn wedi'i gyflwyno yn Gymraeg.
(Dangosir rhif gwreiddiol y Cwestiwn mewn cromfachau)
Rhaid cyflwyno Cwestiynau Ysgrifenedig o leiaf bum diwrnod gwaith cyn y disgwylir iddynt gael eu hateb. Yn ymarferol, bydd Gweinidogion yn ceisio ateb o fewn saith neu wyth diwrnod ond nid oes rheidrwydd arnynt i wneud hynny. Cyhoeddir yr atebion unwaith iddynt gael eu derbyn yn yr iaith y'u cyflwynir ynddi, gyda chyfieithiad i'r Saesneg o ymatebion a roddir yn y Gymraeg.
Gofyn i'r Gweinidog Iechyd a Gwasanaethau Cymdeithasol
Janet Finch-Saunders (Aberconwy): A wnaiff y Gweinidog amlinellu'r meini prawf a ddefnyddir gan y Grŵp Strategaeth Feddyginiaethau Cymru Gyfan i benderfynu pa feddyginiaethau y bydd yn cynnal gwerthusiadau interim mewn perthynas â hwy cyn cael cyngor gan NICE? (WAQ68222)
Derbyniwyd ateb ar 22 Ionawr 2015
Mark Drakeford: The All Wales Medicines Strategy Group (AWMSG) take into account the future work programme of the National Institute for Health and Care Excellence (NICE) when considering whether a medicine will be appraised. AWMSG will not normally consider appraising a medicine if NICE intend to publish their final appraisal of the same product within 12 months of the date of marketing authorisation.
Janet Finch-Saunders (Aberconwy): A wnaiff y Gweinidog nodi ad-daliadau amcangyfrifedig y Cynllun Rheoleiddio Prisiau Fferyllol i Gymru ar gyfer 2014/15 a 2015/16 a datgan a yw'r arian hwn wedi cael ei ddyrannu eto? (WAQ68223)
Derbyniwyd ateb ar 22 Ionawr 2015
Mark Drakeford: The Pharmaceutical Price Regulation Scheme (PPRS) payment estimate for the UK in 2014/15 is £454 million and in 2015/16 is £995 million. The apportionment of these monies to Wales will be based on the expenditure of NHS Wales on branded medicines compared to the other UK countries. The annual reconciliation for monies allocated to Wales in 2014/15 will not be completed until 30 August 2015. All payments to Wales will be spent on improving patients’ health and care.
Janet Finch-Saunders (Aberconwy): A wnaiff y Gweinidog gyhoeddi adolygiad o effaith y cynllun gweithredu i Gymru ar gyfer hepatitis feirysol a gludir yn y gwaed? (WAQ68224)
Derbyniwyd ateb ar 20 Ionawr 2015
Y Gweinidog Iechyd a Gwasanaethau Cymdeithasol (Mark Drakeford): The Blood Borne Viral Hepatitis Action Plan is a five year plan first published in April 2010. The Implementation Board will be evaluating the impact of the Action Plan at the end of its term. A summary report will be published on the Public Health Wales web site.
Janet Finch-Saunders (Aberconwy): A wnaiff y Gweinidog amlinellu cynlluniau ei adran o ran disodli'r cynllun gweithredu i Gymru ar gyfer hepatitis feirysol a gludir yn y gwaed ym mis Ebrill 2015? (WAQ68225)
Derbyniwyd ateb ar 22 Ionawr 2015
Mark Drakeford: The Blood Borne Viral Hepatitis Action Plan has resulted in significant developments in specialist services and this has much increased the capacity of the NHS in Wales to diagnose, treat and care for individuals with chronic viral hepatitis infection. The Action Plan was supported by funding to establish a clinical network. This funding will be maintained and mainstreamed into the work of health boards and Public Health Wales to continue to deliver effective services. We recently concluded a consultation on a Liver Disease Delivery Plan. This Plan incorporates actions to drive further improvement on blood borne viruses such as hepatitis and the implementation arrangements will include monitoring the progress of relevant services.
Janet Finch-Saunders (Aberconwy): A wnaiff y Gweinidog ddatganiad yn amlinellu nifer y bobl yng Nghymru â hepatitis C yn y cyfnod 2010-15, gan gynnwys pobl a gafodd ddiagnosis ac amcangyfrif o ran y nifer nad ydynt wedi cael diagnosis, a pha ganran o'r rhain sydd wedi cyflawni ymateb firolegol parhaus? (WAQ68226)
Derbyniwyd ateb ar 20 Ionawr 2015
Mark Drakeford: Studies suggest that 0.4 per cent of the population in Wales, around 12,000 -14,000 people, have chronic hepatitis C infection. Historic data on confirmed cases of hepatitis C are published on a UK basis by Public Health England. The "Hepatitis C in the UK - 2014 Report" can be found at: https://www.gov.uk/government/publications/hepatitis-c-in-the-uk. Figures 32 and 33 show the latest available data up to 2013.
It is estimated that across Wales in 2011 and 2012 nearly 1,500 individuals with hepatitis C infection were referred for specialist assessment; nearly 1,000 new referrals were seen by treatment services; over 400 individuals commenced on treatment and nearly 200 individuals achieved a sustained virologic response. This data is published by Public Health Wales at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=68681.
Data for 2013 is currently being analysed and will be available in July 2015.
Janet Finch-Saunders (Aberconwy): A wnaiff y Gweinidog nodi faint y mae'r GIG yng Nghymru wedi gwario ar feddyginiaethau hepatitis C rhwng 2010 a 2015? (WAQ68227)
Derbyniwyd ateb ar 22 Ionawr 2015
Mark Drakeford: A wide range of medicines are used in the treatment of patients with hepatitis C and some of these are also used in the treatment of other diseases. In general, prescription data linked to specific disease indications is not collected. It is therefore not possible to give an accurate figure on expenditure for medicines to treat hepatitis C.
Janet Finch-Saunders (Aberconwy): A wnaiff y Gweinidog ddatgan nifer yr unigolion yng Nghymru â haint y feirws hepatitis C a gafodd driniaeth ar gyfer hepatitis C yn y cyfnod rhwng 2010 a 2015, gan gynnwys nifer y rhai a gyflawnodd ymateb firolegol parhaus? (WAQ68228)
Derbyniwyd ateb ar 20 Ionawr 2015
Mark Drakeford: It is estimated that across Wales in 2011 and 2012 over 400 individuals commenced on treatment for hepatitis C and nearly 200 individuals achieved a sustained virologic response following treatment. This data is published by Public Health Wales at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=68681.
Data for 2013 is currently being analysed and will be available in July 2015.